Xvivo Perfusion AB (publ) (XVIPF)
OTCMKTS
· Delayed Price · Currency is USD
32.90
0.00 (0.00%)
May 6, 2025, 4:00 PM EDT
Xvivo Perfusion AB Revenue
Xvivo Perfusion AB had revenue of 218.59M SEK in the quarter ending March 31, 2025, with 17.51% growth. This brings the company's revenue in the last twelve months to 854.98M, up 32.98% year-over-year. In the year 2024, Xvivo Perfusion AB had annual revenue of 822.42M with 37.63% growth.
Revenue (ttm)
854.98M SEK
Revenue Growth
+32.98%
P/S Ratio
11.61
Revenue / Employee
4.50M SEK
Employees
190
Market Cap
989.06M USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 822.42M | 224.87M | 37.63% |
Dec 31, 2023 | 597.54M | 182.25M | 43.88% |
Dec 31, 2022 | 415.29M | 156.91M | 60.73% |
Dec 31, 2021 | 258.39M | 78.53M | 43.66% |
Dec 31, 2020 | 179.86M | -40.98M | -18.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |